Artemether (Synonyms: Dihydroqinghaosu methyl ether; Dihydroartemisinin methyl ether; SM224)

Name: Artemether
Brand: MedChemExpress
SKU: HY-N0402
Rating: 5.0 (3 reviews)

Cat. No.: HY-N0402 Purity: 98.38%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Artemether is an anti-malarial compound that targets drug-resistant strains of falciparum malaria.

For research use only. We do not sell to patients.

CAS No. : 71963-77-4

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
100 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	Get quote
5 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Artemether:

3 Publications Citing Use of MCE Artemether

Others

In Vivo Efficacy Study

: Artemether purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2025 Nov 25;82(1):419.; KCl-induced insulin secretion of islets using 0,100 and 200 µM Artemether.

: Artemether purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2025 Nov 25;82(1):419.; Long-term Artemether (20 mg/kg/d) treatment decreased glucose-induced and KCl-induced insulin secretion by islets.

: Artemether purchased from MedChemExpress. Usage Cited in: Cell Mol Life Sci. 2025 Nov 25;82(1):419.; Immunohistochemical staining of insulin after artemether treatment (Con: DMSO, Art: artemether). Green means insulin expression and blue means DAPI.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Parasite Isoform Specific Products:

View All Isoforms

Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

Biological Activity
Purity & Documentation
References
Customer Review

Description

Artemether is an anti-malarial compound that targets drug-resistant strains of falciparum malaria^[1].

IC₅₀ & Target

Plasmodium

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	8.54 μM Compound: 1d	Anticancer activity against human A549 cells by sulforhodamine B assay Anticancer activity against human A549 cells by sulforhodamine B assay	[PMID: 19819696]
CHO	IC₅₀	> 100 μM Compound: ARM	Cytotoxicity against CHO cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against CHO cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 27448920]
CHO	IC₅₀	> 100 μM Compound: ARM	Cytotoxicity against CHO cells assessed as reduction in cell viability by MTT assay Cytotoxicity against CHO cells assessed as reduction in cell viability by MTT assay	[PMID: 32987134]
Ehrlich	IC₅₀	14.3 μM Compound: 3	Cytotoxicity against mouse EAC after 3 days by MTT assay Cytotoxicity against mouse EAC after 3 days by MTT assay	[PMID: 8350087]
HCT-116	IC₅₀	8.6 μM Compound: ATM	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth by Cell-titer Glo luminescent assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth by Cell-titer Glo luminescent assay	[PMID: 38287228]
HCT-15	IC₅₀	9.66 μM Compound: 1d	Anticancer activity against human HCT15 cells by sulforhodamine B assay Anticancer activity against human HCT15 cells by sulforhodamine B assay	[PMID: 19819696]
HFF	IC₅₀	0.31 μM Compound: Artemether	Antiparasitic activity against Toxoplasma gondii 2F infected in HFF cells assessed as beta galactosidase activity after 5 days Antiparasitic activity against Toxoplasma gondii 2F infected in HFF cells assessed as beta galactosidase activity after 5 days	[PMID: 20373807]
HepG2	IC₅₀	< 1 μM Compound: Artemether	Antimalarial activity against sporozoite stage of Plasmodium yoelii assessed as invasion of human HepG2 cells expressing CD81 incubated for 2 hrs prior to inoculation measured after 1 hr by immunofluorescence assay in presence of penicillin/streptomycin Antimalarial activity against sporozoite stage of Plasmodium yoelii assessed as invasion of human HepG2 cells expressing CD81 incubated for 2 hrs prior to inoculation measured after 1 hr by immunofluorescence assay in presence of penicillin/streptomycin	[PMID: 23927658]
PBMC	IC₅₀	> 100000 nM Compound: 3	Cytotoxicity against PHA-stimulated human PBMC cells after 48 hrs by Alamar Blue assay Cytotoxicity against PHA-stimulated human PBMC cells after 48 hrs by Alamar Blue assay	[PMID: 23673218]
SK-MEL-2	IC₅₀	7.24 μM Compound: 1d	Anticancer activity against human SK-MEL-2 cells by sulforhodamine B assay Anticancer activity against human SK-MEL-2 cells by sulforhodamine B assay	[PMID: 19819696]
SK-OV-3	IC₅₀	8.03 μM Compound: 1d	Anticancer activity against human SKOV3 cells by sulforhodamine B assay Anticancer activity against human SKOV3 cells by sulforhodamine B assay	[PMID: 19819696]
T-cell	IC₅₀	3.82 x 10^-6 M Compound: Artemether	In vitro concentration of compound required to inhibit ConA-induced T cell proliferation to 50% in BALB/c mice In vitro concentration of compound required to inhibit ConA-induced T cell proliferation to 50% in BALB/c mice	[PMID: 15999998]
XF498	IC₅₀	9.1 μM Compound: 1d	Anticancer activity against human XF498 cells by sulforhodamine B assay Anticancer activity against human XF498 cells by sulforhodamine B assay	[PMID: 19819696]

In Vitro

Artemether (0-200 μg/mL, 24-72 h) inhibits rat C6 glioma cell growth in a dose- and time-dependent manner^[2].
Artemether (0-10 μM, 72 h) inhibits RANKL-induced osteoclast (osteoclast precursor cells (BMMs)) formation and related gene expression (TRAP, NFATc1, V-ATPase-d2, CTSK, DC-STAMP, MMP-9)^[2].
Artemether (48 or 96 h) inhibits ConA- or alloantigen-induced BALB/c splenocyte proliferation (IC₅₀: 6.3 and 3.5 μM)^[4].
Artemether (0-50 μM, 16-36 h) inhibits production of the IL-2 and IFN-γ in BALB/c splenocyte^[4].
Artemether (0-50 μM, 72 h) inhibits ConA-induced splenocyte, CD4+T- and CD8+ T-cell divisions, and inhibits cell cycle progression through G1/S transition^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[3]

Cell Line:	RAW264.7 cells (treated with 100 ng/mL RANKL)
Concentration:	10 μM
Incubation Time:	6 h
Result:	Inhibited the activation of MAPK subfamilies, including ERK, JNK, and p38.

Cell Cycle Analysis^[4]

Cell Line:	ConA-stimulated T lymphocytes
Concentration:	1, 10 and 50 μM
Incubation Time:	72 h
Result:	Arrested 47, 56 and 91% (at 1, 10 and 50 μM) of the cells at G0/G1 phases, respectively.

In Vivo

Artemether (0-66 mg/kg, p.o.) inhibits tumor growth and angiogenesis in SD rats bearing C6 glioma cells^[2].
Artemether (10 mg/kg, i.p., 8 days) protects mice against LPS-induced osteolytic bone loss^[3].
Artemether (50 and 100 mg/kg, p.o.) inhibits T-cell-mediated immune responses (ear swelling) in DNFB-induced DTH model in BALB/c mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	LPS (5 mg/kg) treated mice^[3]
Dosage:	10 mg/kg
Administration:	i.p., 8 days
Result:	Prevented LPS induced osteolytic bone loss and the reduction in bone volume. Increased bone volume/total volume (BV/TV), decreased osteoclast surface/bone surface (Oc.S/BS) and number of TRAP-positive cells.

Clinical Trial

Molecular Weight

298.37

Formula

C₁₆H₂₆O₅

CAS No.

71963-77-4

Appearance

Solid

Color

White to off-white

SMILES

C[C@H]1[C@@H](OC)O[C@@]2([H])[C@]34[C@@]([C@H](C)CC[C@]41[H])([H])CC[C@@](O2)(C)OO3

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (335.15 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.3515 mL	16.7577 mL	33.5154 mL
5 mM	0.6703 mL	3.3515 mL	6.7031 mL
10 mM	0.3352 mL	1.6758 mL	3.3515 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.38 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.38 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (8.38 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 4

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: ≥ 1.25 mg/mL (4.19 mM); Clear solution
Protocol 5

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (4.19 mM); Clear solution
Protocol 6

Add each solvent one by one: 5% DMSO 95% Corn Oil
Solubility: 1.25 mg/mL (4.19 mM); Suspended solution; Need ultrasonic

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 15% Cremophor EL 85% Saline
Solubility: 6.02 mg/mL (20.18 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.20%

Select Batch:

Data Sheet (285 KB) SDS (392 KB)

COA (259 KB) HNMR (135 KB)

Handling Instructions (2659 KB)

References

[1]. Xiao, S., et al., Recent investigations of artemether, a novel agent for the prevention of schistosomiasis japonica, mansoni and haematobia. Acta Trop, 2002. 82(2): p. 175-81. [Content Brief]

[2]. Wu, Z.P., et al., Inhibitive effect of artemether on tumor growth and angiogenesis in the rat C6 orthotopic brain gliomas model. Integr Cancer Ther, 2009. 8(1): p. 88-92. [Content Brief]

[3]. Wu H, et al. Artemether attenuates LPS-induced inflammatory bone loss by inhibiting osteoclastogenesis and bone resorption via suppression of MAPK signaling pathway. Cell Death Dis. 2018 May 1;9(5):498. [Content Brief]

[4]. Wang JX, et al. Investigation of the immunosuppressive activity of artemether on T-cell activation and proliferation. Br J Pharmacol. 2007 Mar;150(5):652-61. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.3515 mL	16.7577 mL	33.5154 mL	83.7886 mL
	5 mM	0.6703 mL	3.3515 mL	6.7031 mL	16.7577 mL
	10 mM	0.3352 mL	1.6758 mL	3.3515 mL	8.3789 mL
	15 mM	0.2234 mL	1.1172 mL	2.2344 mL	5.5859 mL
	20 mM	0.1676 mL	0.8379 mL	1.6758 mL	4.1894 mL
	25 mM	0.1341 mL	0.6703 mL	1.3406 mL	3.3515 mL
	30 mM	0.1117 mL	0.5586 mL	1.1172 mL	2.7930 mL
	40 mM	0.0838 mL	0.4189 mL	0.8379 mL	2.0947 mL
	50 mM	0.0670 mL	0.3352 mL	0.6703 mL	1.6758 mL
	60 mM	0.0559 mL	0.2793 mL	0.5586 mL	1.3965 mL
	80 mM	0.0419 mL	0.2095 mL	0.4189 mL	1.0474 mL
	100 mM	0.0335 mL	0.1676 mL	0.3352 mL	0.8379 mL

Artemether Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Artemether71963-77-4Dihydroqinghaosu methyl ether Dihydroartemisinin methyl ether SM224SM224SM 224SM-224ParasiteInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Artemether (Synonyms: Dihydroqinghaosu methyl ether; Dihydroartemisinin methyl ether; SM224)

Customer Review

Other Forms of Artemether:

Artemether Related Antibodies

3 Publications Citing Use of MCE Artemether

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Parasite Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Artemether Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Artemether Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report